Marco Siano
University of St. Gallen
CancerSurgeryOncologyAdverse effectClinical endpointVemurafenibLung cancerHead and neck cancerChemotherapyHead and neck squamous-cell carcinomaPerformance statusMelanomaImmunotherapyPanitumumabCobimetinibCetuximabPembrolizumabCancer researchRadiation therapyMedicine
Publications 45
#1Marco SianoH-Index: 12
#2Nicholas Pavlidis (UoI: University of Ioannina)H-Index: 68
Last. Alberto CostaH-Index: 49
view all 8 authors...
The European School of Oncology (ESO) embarked on an online educational project, starting with live sessions in 2008 (e-ESO). Our scholars and young oncologists identified the need to be offered independent high-level online education with contributions from experts around the world, free of charge and available at any moment. We report on various types of e-sessions, such as grand-rounds, highlights, debates, clinical cases and other sessions. Our audience has grown over the last decade, reachi...
Until recently, standard treatment for advanced melanoma comprised basically dacarbazine and interleukin-2, leading to low response rates and significant toxicity. These days, new treatments such as immunotherapy (anti-CTLA4 and anti-PD1 antibodies) and targeted therapy with BRAF/MEK-inhibitor combinations for patients harboring a BRAF mutation are available. In BRAF wild-type patients harboring an NRAS mutation, not fit for immunotherapy treatment options are still dismal. We describe an 84-yea...
#1Silvano Gnesin (UNIL: University of Lausanne)H-Index: 9
#2Joachim Müller (HSG: University of St. Gallen)H-Index: 3
Last. Niklaus Schaefer (UNIL: University of Lausanne)H-Index: 21
view all 14 authors...
BACKGROUND: The folate receptor alpha (FRalpha) is an interesting target for imaging and therapy of different cancers. We present the first in-human radiation dosimetry and radiation safety results acquired within a prospective, multicentric trial (NCT03242993) evaluating the (18)F-AzaFol (3'-aza-2'-[(18)F]fluorofolic acid) as the first clinically assessed PET tracer targeting the FRalpha. MATERIAL AND METHODS: Six eligible patients presented a histologically confirmed adenocarcinoma of the lung...
8 CitationsSource
#1Valerie Cristina (CHUV: University Hospital of Lausanne)H-Index: 2
#1Valerie CristinaH-Index: 4
Last. Marco SianoH-Index: 12
view all 5 authors...
Head and neck squamous cell carcinoma (HNSCC) is often diagnosed at an advanced stage and has a dismal prognosis. Nearly 10 years after the approval of cetuximab, anti-PD1/PD-L1 checkpoint inhibitors are the first drugs that have shown any survival benefit for the treatment on platinum-refractory recurrent/metastatic (R/M) HNSCC. Furthermore, checkpoint inhibitors are better tolerated than chemotherapy. The state of the art in the treatment of R/M HNSCC is changing, thanks to improved results fo...
5 CitationsSource
#1Marco Siano (HSG: University of St. Gallen)H-Index: 12
#2Paul Martin Putora (University of Bern)H-Index: 16
Last. Olgun Elicin (University of Bern)H-Index: 12
view all 14 authors...
Background: The Head and Neck Cancer Working Group of Swiss Group for Clinical Cancer Research (SAKK) has investigated the level of consensus (LOC) and discrepancy in everyday practice of diagnosis and treatment in head and neck cancer. Materials and Methods: An online survey was iteratively generated with 10 Swiss university and teaching hospitals. LOC below 50% was defined as no agreement, while higher LOC were arbitrarily categorized as low (51-74), moderate (75-84%), and high (≥85%). Results...
6 CitationsSource
#1Paolo Bossi (University of Brescia)H-Index: 37
#2Raffaele GiustiH-Index: 13
Last. Marco Siano (HSG: University of St. Gallen)H-Index: 12
view all 10 authors...
Abstract Head and neck cancer (HNC) can have a devastating impact on patient’s lives as both disease and treatment may affect the ability to speak, swallow and breathe. These conditions limit the oral intake of food and drugs, reduce social functioning and impact on patient’s quality of life. Up to 80% of patients suffering from HNC have pain due to the spread of the primary tumor, because of consequences of surgery, or by developing oral mucositis, dysphagia or neuropathy as toxic side effects ...
7 CitationsSource
#1Emanuel Lengwiler (UZH: University of Zurich)H-Index: 1
#2Susanne StampfH-Index: 7
Last. Günther F.L. Hofbauer (UZH: University of Zurich)H-Index: 36
view all 9 authors...
There is a large body of evidence indicating that 4 to 5% of solid organ transplant recipients develop a malignancy after transplantation, which corresponds to an approximately two- to four-fold elevated risk compared to the general population.
6 CitationsSource
#1Marco Siano (HSG: University of St. Gallen)H-Index: 12
#2Vittoria EspeliH-Index: 4
Last. Markus Joerger (HSG: University of St. Gallen)H-Index: 26
view all 3 authors...
Background:Delay of systemic treatment in recurrent/metastatic head and neck squamous cell cancer (r/mHNSCC) has never been assessed. Whether time span to start systemic treatment affects survival ...
#1Mirjam Fässler (Kantonsspital St. Gallen)H-Index: 4
#2Stefan Diem (Kantonsspital St. Gallen)H-Index: 10
Last. Lukas FlatzH-Index: 24
view all 22 authors...
Long-term survival of stage IV melanoma patients has improved significantly with the development of immune checkpoint inhibitors (CIs). Reliable biomarkers to predict response and clinical outcome are needed. We investigated the role of melanoma-associated antibodies as predictive markers for CI therapy in two independent cohorts. In cohort 1, a prospective study, we measured specific antibodies before treatment, after one week and after six to nine weeks of treatment. Cohort 2 consisted of seru...
15 CitationsSource
#1Marco Siano (HSG: University of St. Gallen)H-Index: 12
#2Salvatore AlfieriH-Index: 17
Last. Laura D. LocatiH-Index: 31
view all 7 authors...
Purpose:Two tyrosine kinase inhibitors (TKIs), vandetanib and cabozantinib, have been approved for recurrent/metastatic (R/M) medullary thyroid carcinoma (MTC). To date, it is still debated when an...
1 CitationsSource